Wire Stories
Bio-Thera Solutions Initiates Phase III Clinical Trial for BAT2306, a Proposed Biosimilar of Cosentyx� (Secukinumab)
GUANGZHOU, China–(BUSINESS WIRE)–#ActiveAnkylosingSpondylitis–Bio-Thera Solutions, Ltd. (688177.SH), a commercial-stage pharmaceutical company, today announced that dosing has begun in a Phase III clinical study...